Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Recruiting 2Suspended 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 2Classical hematology 2

Conditions

Leukemia, Myeloid, Acute 160Myelodysplastic Syndromes 44Leukemia, Myelomonocytic, Chronic 25Leukemia 16Myeloproliferative Disorders 11Recurrence 9Hematologic Neoplasms 8Neoplasms 6Lymphoma, T-Cell, Peripheral 6Primary Myelofibrosis 5Leukemia, Biphenotypic, Acute 5Anemia, Refractory, with Excess of Blasts 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm, Residual 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Leukemia, Monocytic, Acute 4Hematologic Diseases 4GATA2 Deficiency 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Polycythemia Vera 2Lymphoma, T-Cell 2

Interventions

venetoclax 4Azacitidine 4Specimen Handling 3regorafenib 1iadademstat 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Whole-Body Irradiation 1Vorinostat 1Thiotepa 1Tacrolimus 1Methotrexate 1Lenalidomide 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
GATA2 Deficiency × Azacitidine × 1 year × Clear all
NCT06372717 2026-06-01

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

Apollo Therapeutics Ltd

Phase 1 Recruiting
100 enrolled
Classical hematologyOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT06454409 2025-11-19

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical Center

Phase 1 Suspended
20 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06357182 2025-08-12

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

OHSU Knight Cancer Institute

Phase 1 Recruiting
24 enrolled
Other hematologic neoplasm

GATA2 Deficiency, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡